Platform

The PATHOMIQ AI Platform is Powered by Our Phenotype Atlas

This powerful asset allows us to quickly deploy our platform to new and specific use-cases using only a minimal amount of outcome data.

The First Of Its Kind

PATHOMIQ AI Platform

Our comprehensive phenotype atlas combines expert pathologist supervision with cutting edge AI-learned information. Trained using thousands of slides spanning multiple tissues from a diverse set of medical institutions, this powerful asset allows us to quickly deploy our platform to new and specific use-cases using only a minimal amount of outcome data.

Outcome Prediction

The PATHOMIQ AI Platform outperforms clinical and genomic gold standards. We have shown to accurately predict risk of metastasis and response to anti-androgen therapy in prostate cancer, risk of chemotherapy and hormonal therapy resistance in ER+/HER2- breast cancer, as well as pathologic complete response in triple negative breast cancer.

Efficient Screening Capability

Our platform can predict genotypes and molecular alterations directly from H&E-stained WSIs with high accuracy, enabling timely and optimal treatment decision-making for positive clinical outcomes.

The PATHOMIQ AI Platform Predicts Alterations in Prostate and Breast.

Biomarker Discovery

Our platform identifies regions of interest that are predictive to specific therapy response, allowing for focused molecular analysis.

Phenotype-guided ROIs Capture Molecular Changes.

Precision Cancer Screening

Our powerful method allows for precision gland-level cancer grading to improve accuracy of pathologists.

Testimonials

Hear From the Experts

The AI-powered PATHOMIQ tool holds promise to change that and identify those at highest risk of recurrence by image-based analysis of image-based analysis of initial biopsy or prostatectomy samples. This technology is non-destructive, has fast turn-around time, identifies “hot spots” that will allow deeper proteogenomic analysis to help identify the drivers of progression, and as such is a promising approach to define more personalized outcome predictions and therapies.

Eric A. KleinChair of the Glickman Urological & Kidney Institute, Professor of Surgery, Lerner College of Medicine, Cleveland Clinic

I am excited to see the high degree of accuracy in PATHOMIQ AI-powered tool for identifying these patients from images of their primary biopsies that will immensely help better decision making for each patient. Additionally, PATHOMIQ’s image based, fast turn-over and non-destructive analysis will allow deeper genomic analysis of the cancer driving areas to refine personalized therapies at an earlier stage of the disease leading to better success rate with lesser side effects.

Janak D. Desai, MS, MCh, FRCSUrologist, Samved Urology Hospital

I am excited to co-develop with the PATHOMIQ team, the PATHOMIQ_PRAD AI model for prostate cancer treatment response prediction and identify high-risk prostate cancer patients who experience early metastasis post-surgery. This AI model has outperformed currently used markers in both Caucasian and African American patient cohorts for a much-improved outcome.

Ashutosh Tewari, MD, MBBSDirector of Robotic Prostatectomy, Precision Urology Director, Prostate Cancer Program

A biomarker that can reliably predict response to chemotherapies at the time of the initial diagnosis would have far reaching clinical implications such as the personalization of cytotoxic and immunotherapy regimens that would optimize both safety and efficacy. We are very excited about the performance of PATHOMIQ’s AI-enabled morphometric biomarker from H&E slides that could be translated into the clinic for personalized treatment selection for each patient in the near future.

Debasish Tripathy, MDChairman, Department of Breast Medical Oncology, MD Anderson Cancer Center

This is the first demonstration of using an AI tool on digitized H&E tissue images to predict response to NAC in patients with TNBC with high accuracy.

Savitri Krishnamurthy, MDProfessor, Department of Pathology, MD Anderson Cancer Center

The Minds Behind Our Mission.

Meet the Team

PATHOMIQ AI, headquartered in Silicon Valley, USA, was founded by a multidisciplinary team of outstanding biomarker discovery researchers, data scientists, and clinicians with 100+ man-years of experience in their areas of specialty.